About: A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
Creator	Mundt, Wolfgang Kistner, Otfried Brühl, Peter Crowe, Brian Gerencer, Marijan Grillberger, Leopold Hitter, Elisabeth Reiter, Manfred Savidis-Dacho, Helga Spruth, Martin Tauer, Christa Barrett, P
Source	Elsevier; Medline; PMC
abstract	Abstract A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)3 had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-γ and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.
has issue date	2006-01-30(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2005.08.055
bibo:pmid	16214268
has license	els-covid
sha1sum (hex)	da95b9a06e4d0db35503357ccbec0e23c973b85f
schema:url	https://doi.org/10.1016/j.vaccine.2005.08.055
resource representing a document's title	A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
has PubMed Central identifier	PMC7115667
has PubMed identifier	16214268
schema:publication	Vaccine
resource representing a document's body	covid:da95b9a06e4d0db35503357ccbec0e23c973b85f#body_text
is schema:about of	named entity 'levels' named entity 'high' named entity 'developed' named entity 'involving' named entity 'cell mediated immunity' named entity 'procedure' named entity 'prevention' named entity 'developed' named entity 'replication' named entity 'stimulation' named entity 'INACTIVATED' named entity 'TWICE' named entity 'ADDITION' named entity 'CELL MEDIATED IMMUNITY' named entity 'DEMONSTRATED' named entity '90%' named entity 'CANDIDATE' named entity 'PROTECTION' named entity 'MARGIN' named entity 'IMMUNOGENICITY' named entity 'MEASURED' named entity 'S PROTEIN' named entity 'PROCEDURE' named entity 'ORDER' named entity 'NEUTRALISING ANTIBODY' named entity 'INACTIVATED VACCINE' named entity 'PROTECTIVE IMMUNITY' named entity 'CORONAVIRUS VACCINE' named entity 'CORRELATED' named entity 'RESPECT' named entity 'SERUM PROTEIN' named entity 'USE OF' named entity 'ANTIBODY TITRE' named entity 'USING' named entity 'RESPONSES' named entity 'A MINOR' named entity 'INVOLVING' named entity 'PROTEIN ' named entity 'ANTIBODY' named entity 'VIRUS' named entity 'INACTIVATED' named entity 'MOUSE MODEL' named entity 'FREE' named entity 'DOUBLE' named entity 'LARGE SCALE' named entity 'NEUTRALISING ANTIBODIES' named entity 'VACCINATION' named entity 'ELICITED BY' named entity 'STEP' named entity 'REPLICATION' named entity 'PREVENTION OF' named entity 'MICE' named entity 'SEQUENTIAL' named entity 'FERMENTER' named entity 'STIMULATION' named entity 'ANTIBODY TITRES' named entity 'RESIDUAL' named entity 'EXTREMELY' named entity 'RESPIRATORY TRACT' named entity 'INTERLEUKIN-4 ' named entity 'ENSURE' named entity 'INTRANASAL' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'ADJUVANT' named entity 'CORONAVIRUS' named entity 'CULTURES' named entity 'EFFECT' named entity 'U.V.' named entity 'MANUFACTURED' named entity 'CHALLENGE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software